IPO - Capital Raise
Company: East 33
Sector : Agriculture/Oyster Production
Description: The East 33 Group is one of Australia’s largest producers and suppliers of premium Sydney Rock
Oysters (SROs). Based in the Great Lakes area of New South Wales’ mid-north coast. The Sydney Rock Oyster is Australia’s prestige native oyster and
naturally thrives in less than 30 locations on the east coast of Australia. These pristine waterways and undisputed provenance make the SRO a highly
unique and exceptionally rare product, with an estimated one SRO being produced for every 36,000 oysters grown globally.
Some key figures:
- Historic EBITDA of FY19 $4.5M forecast to be $8M in FY22 and $20M in FY23
- 234% volume growth in oysters from 6M in FY19 to 15M in FY22
East 33 is raising A$32M in a IPO on the ASX.
The East 33 IPO closes on the 16th November 2020.
Company: Imagine Intelligent Materials
Sector: Technology - IOT
Type: Senior Convertible Note
Description: Imagine Intelligent Materials is the leading Australian developer of graphene-based coatings for industrial textiles and
Imagine has developed a breakthrough 'sensing mat' device called On-Q to help people and businesses with social distancing safety measures.
Imagine is raising A$1.5M via a Senior Convertible Note (SCN).
There will be a live streaming presentation of Imagines' new On-Q sensing mat on Wednesday 18th November 11am - 11:30am AEDT to register for the event
please click here
Click below to view a video presentation of the new On-Q mat.
Company: Pallas Capital
Sector : Property
Type: Secured Bond
Description: Pallas Capital is a specialist commercial real estate financier and investment manager and a wholly owned subsidiary of Pallas
Group. Established in 2016, Pallas specialises in the provision of structured debt and equity products to well-seasoned Australian real estate asset
owners and developers, providing excellent risk adjusted returns to its investor base.
With cash rates at an all time low, Pallas Capital is offering a high yield opportunity.
Pallas Capital is raising up to A$100m; initial issue c.A$30m. A fixed coupon of 7.5% p.a. is payable over a 4 year term in denominations of A$10,000.
Company: Pharmaxis (ASX:PXS)
Sector : Pharmaceutical
Type: Investor Centre
Description: Pharmaxis (ASX:PXS) announced the United States Food and Drug Administration (FDA) has approved Bronchitol® (mannitol) as
add-on maintenance therapy to improve pulmonary function in cystic fibrosis (CF) patients 18 years of age and older. The product, developed by Pharmaxis
in Australia, has been steered through final stages of FDA approval by US licensee Chiesi Farmaceutici SpA (Chiesi).
Pharmaxis also announced details of the clinical development plan for its lead drug pipeline asset being studied for the bone marrow cancer myelofibrosis.
PrimaryMarkets now operates an Investor Centre for Pharmaxis, a dedicated online Platform to support investor awareness and market eduction.
Current Market Capitalisation is A$39.28M
Read full releases: